Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery
Background: This study aimed to evaluate the clinical outcomes and dose-volume parameters of computed tomography CT-based brachytherapy for the vaginal recurrence of uterine cancer after hysterectomy. Methods: We evaluated 22 uterine cancer patients treated with CT-based brachytherapy for vaginal re...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
IMR Press
2021-06-01
|
| Series: | Clinical and Experimental Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | https://www.imrpress.com/journal/CEOG/48/3/10.31083/j.ceog.2021.03.2437 |
| _version_ | 1811256336461070336 |
|---|---|
| author | Keiko Nemoto Murofushi Reiko Tanaka Ayako Ohkawa Haruko Numajiri Toshiyuki Okumura Hideyuki Sakurai |
| author_facet | Keiko Nemoto Murofushi Reiko Tanaka Ayako Ohkawa Haruko Numajiri Toshiyuki Okumura Hideyuki Sakurai |
| author_sort | Keiko Nemoto Murofushi |
| collection | DOAJ |
| description | Background: This study aimed to evaluate the clinical outcomes and dose-volume parameters of computed tomography CT-based brachytherapy for the vaginal recurrence of uterine cancer after hysterectomy. Methods: We evaluated 22 uterine cancer patients treated with CT-based brachytherapy for vaginal recurrence between December 2010 and August 2015. Interstitial brachytherapy (ISBT) was used when the vaginal tumor was thicker than 5 mm and/or located at extended extravaginal tissue, whereas intercavitary brachytherapy was performed if it was 5 mm or thinner. Results: Overall, 11 patients had cervical cancer, and 11 had endometrial cancer. The median pretreatment tumor size on magnetic resonance imaging was 17 mm (range, 0–45 mm). Four patients had vaginal recurrence recognized only in the gynecological examination. The primary location of recurrence was the vagina, with extravaginal extension observed in 9 patients. Seventeen patients (77%) received external beam radiotherapy and brachytherapy. ISBT was performed in 12 patients (55%). The median clinical target volume (CTV) D90 was 69.2 Gy (62.6–72.8 Gy). The median D2cc of the bladder, sigmoid, and rectum were 70.2 (63.8–77.6), 37.4 (30.0–43.6), and 52.8 Gy (38.6–63.5 Gy), respectively. Complete response was reached in all patients. The 5-year overall survival rate and local control rate (LC) were 84.8 and 95.5%, respectively. No patient experienced grade ≥3 complications. Conclusions: CT-based brachytherapy has the potential to become an essential treatment for vaginal recurrences of uterine cancer after hysterectomy as it can achieve good LC without increasing the rate of late complications for selected patients with less recurrences. |
| first_indexed | 2024-04-12T17:39:40Z |
| format | Article |
| id | doaj.art-6c5349dca8474e3e87e986b921dbc7e1 |
| institution | Directory Open Access Journal |
| issn | 0390-6663 |
| language | English |
| last_indexed | 2024-04-12T17:39:40Z |
| publishDate | 2021-06-01 |
| publisher | IMR Press |
| record_format | Article |
| series | Clinical and Experimental Obstetrics & Gynecology |
| spelling | doaj.art-6c5349dca8474e3e87e986b921dbc7e12022-12-22T03:22:51ZengIMR PressClinical and Experimental Obstetrics & Gynecology0390-66632021-06-0148360160610.31083/j.ceog.2021.03.2437S0390-6663(21)00154-8Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgeryKeiko Nemoto Murofushi0Reiko Tanaka1Ayako Ohkawa2Haruko Numajiri3Toshiyuki Okumura4Hideyuki Sakurai5Faculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, JapanFaculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, JapanFaculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, JapanFaculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, JapanFaculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, JapanFaculty of Medicine, Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, 305-8576 Ibaraki, JapanBackground: This study aimed to evaluate the clinical outcomes and dose-volume parameters of computed tomography CT-based brachytherapy for the vaginal recurrence of uterine cancer after hysterectomy. Methods: We evaluated 22 uterine cancer patients treated with CT-based brachytherapy for vaginal recurrence between December 2010 and August 2015. Interstitial brachytherapy (ISBT) was used when the vaginal tumor was thicker than 5 mm and/or located at extended extravaginal tissue, whereas intercavitary brachytherapy was performed if it was 5 mm or thinner. Results: Overall, 11 patients had cervical cancer, and 11 had endometrial cancer. The median pretreatment tumor size on magnetic resonance imaging was 17 mm (range, 0–45 mm). Four patients had vaginal recurrence recognized only in the gynecological examination. The primary location of recurrence was the vagina, with extravaginal extension observed in 9 patients. Seventeen patients (77%) received external beam radiotherapy and brachytherapy. ISBT was performed in 12 patients (55%). The median clinical target volume (CTV) D90 was 69.2 Gy (62.6–72.8 Gy). The median D2cc of the bladder, sigmoid, and rectum were 70.2 (63.8–77.6), 37.4 (30.0–43.6), and 52.8 Gy (38.6–63.5 Gy), respectively. Complete response was reached in all patients. The 5-year overall survival rate and local control rate (LC) were 84.8 and 95.5%, respectively. No patient experienced grade ≥3 complications. Conclusions: CT-based brachytherapy has the potential to become an essential treatment for vaginal recurrences of uterine cancer after hysterectomy as it can achieve good LC without increasing the rate of late complications for selected patients with less recurrences.https://www.imrpress.com/journal/CEOG/48/3/10.31083/j.ceog.2021.03.2437vaginal recurrencehigh-dose-rate brachytherapyintracavitary brachytherapyinterstitial brachytherapyimage-guided adaptive brachytherapy |
| spellingShingle | Keiko Nemoto Murofushi Reiko Tanaka Ayako Ohkawa Haruko Numajiri Toshiyuki Okumura Hideyuki Sakurai Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery Clinical and Experimental Obstetrics & Gynecology vaginal recurrence high-dose-rate brachytherapy intracavitary brachytherapy interstitial brachytherapy image-guided adaptive brachytherapy |
| title | Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery |
| title_full | Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery |
| title_fullStr | Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery |
| title_full_unstemmed | Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery |
| title_short | Outcomes and dose—volume parameters for computed tomography-based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery |
| title_sort | outcomes and dose volume parameters for computed tomography based brachytherapy planning for vaginal recurrence of uterine cancer primarily treated with surgery |
| topic | vaginal recurrence high-dose-rate brachytherapy intracavitary brachytherapy interstitial brachytherapy image-guided adaptive brachytherapy |
| url | https://www.imrpress.com/journal/CEOG/48/3/10.31083/j.ceog.2021.03.2437 |
| work_keys_str_mv | AT keikonemotomurofushi outcomesanddosevolumeparametersforcomputedtomographybasedbrachytherapyplanningforvaginalrecurrenceofuterinecancerprimarilytreatedwithsurgery AT reikotanaka outcomesanddosevolumeparametersforcomputedtomographybasedbrachytherapyplanningforvaginalrecurrenceofuterinecancerprimarilytreatedwithsurgery AT ayakoohkawa outcomesanddosevolumeparametersforcomputedtomographybasedbrachytherapyplanningforvaginalrecurrenceofuterinecancerprimarilytreatedwithsurgery AT harukonumajiri outcomesanddosevolumeparametersforcomputedtomographybasedbrachytherapyplanningforvaginalrecurrenceofuterinecancerprimarilytreatedwithsurgery AT toshiyukiokumura outcomesanddosevolumeparametersforcomputedtomographybasedbrachytherapyplanningforvaginalrecurrenceofuterinecancerprimarilytreatedwithsurgery AT hideyukisakurai outcomesanddosevolumeparametersforcomputedtomographybasedbrachytherapyplanningforvaginalrecurrenceofuterinecancerprimarilytreatedwithsurgery |